248 related articles for article (PubMed ID: 23475203)
21. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity.
Cheng J; Ma X; Krausz KW; Idle JR; Gonzalez FJ
Drug Metab Dispos; 2009 Aug; 37(8):1611-21. PubMed ID: 19460945
[TBL] [Abstract][Full Text] [Related]
22. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
23. Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver.
Sachar M; Li F; Liu K; Wang P; Lu J; Ma X
Chem Res Toxicol; 2016 Aug; 29(8):1293-7. PubMed ID: 27438535
[TBL] [Abstract][Full Text] [Related]
24. Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury.
Wang C; Fan RQ; Zhang YX; Nie H; Li K
World J Gastroenterol; 2016 Nov; 22(44):9775-9783. PubMed ID: 27956801
[TBL] [Abstract][Full Text] [Related]
25. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
[TBL] [Abstract][Full Text] [Related]
26. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
27. Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis.
Linna O; Uhari M
Eur J Pediatr; 1980 Sep; 134(3):227-9. PubMed ID: 6968680
[TBL] [Abstract][Full Text] [Related]
28. [Antitubercular drug-induced liver injuries].
Guo Y; Cui D
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
[No Abstract] [Full Text] [Related]
29. [Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin (author's transl)].
Poupon RY; Meyniel D; Petit J; Gustot P; Darnis F
Ann Med Interne (Paris); 1979; 130(6-7):371-5. PubMed ID: 496138
[TBL] [Abstract][Full Text] [Related]
30. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
[TBL] [Abstract][Full Text] [Related]
31. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
32. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
[TBL] [Abstract][Full Text] [Related]
33. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
[TBL] [Abstract][Full Text] [Related]
34. [Addisonian crises induced by rifampicin].
Campos-Varela I; Perich-Jackson D; Ferrer-Sancho J
Arch Bronconeumol; 2006 Jul; 42(7):376. PubMed ID: 16945269
[No Abstract] [Full Text] [Related]
35. Effect of different oral doses of isoniazid-rifampicin in rats.
Rana SV; Pal R; Vaiphie K; Singh K
Mol Cell Biochem; 2006 Sep; 289(1-2):39-47. PubMed ID: 16583132
[TBL] [Abstract][Full Text] [Related]
36. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
37. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
39. [Drug-induced hepatitis during a treatment associating isoniazid and rifampicin].
Jean R; Bonnet H; Pages P; Dumas R; Greze J
Ann Pediatr (Paris); 1972 Apr; 19(4):307-11. PubMed ID: 5075678
[No Abstract] [Full Text] [Related]
40. Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine.
Attri S; Rana SV; Vaiphei K; Sodhi CP; Katyal R; Goel RC; Nain CK; Singh K
Hum Exp Toxicol; 2000 Sep; 19(9):517-22. PubMed ID: 11204554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
